Odyssey Therapeutics Q3 2026 net loss widens 50% to $53.1 million
ODTX•Odyssey Therapeutics’ third-quarter 2026 net loss widened 50% year over year to $53.1 million. It reported $387 million in cash, cash equivalents and marketable securities, expected to fund operations into the second half of 2028.
1. Quarterly results and outlook
Research and development expenses rose 60% to $42.1 million, primarily due to higher external costs for advancing clinical and preclinical programs. The company expects topline induction results for OD-001 from Phase 2b monotherapy and Phase 2a combination trials in the second half of 2027. After completing IND-enabling studies, it expects to begin an OD-002 Phase 1/2a trial in the first half of 2027.
